How do we confirm the project after execution?

Once the project is confirmed, we provide a detailed project plan, including required sample quantities and experimental details. After mutual agreement on the plan, we officially begin the project.

How is project progress monitored?

Throughout the project, we regularly update clients on the progress, animal status, and any necessary adjustments. Clients are kept informed with timely reports, ensuring transparency and collaboration.

What happens when the project is completed?

Upon completion, we provide the client with a comprehensive report summarizing the project's results. We also arrange for the shipment of any produced samples. Discussions regarding the results and next steps will follow.

What does after-sales support include?

After the project is completed, we store the data for future reference and provide any necessary assistance with follow-up or additional analysis if required.

How long does the entire process take?

The timeline depends on the scope and complexity of the project. During the pricing inquiry stage, we provide an estimated timeline, which is refined after the project execution plan is confirmed.

Digestive System Disease Modeling & Pharmacodynamics Services

Introduction

Digestive system diseases encompass a wide range of conditions affecting the gastrointestinal (GI) tract, including the esophagus, stomach, intestines, liver, and pancreas. Common examples include acid reflux disease, Crohn's disease, ulcerative colitis, liver cirrhosis, and pancreatic cancer. These diseases can arise from genetic, environmental, and lifestyle factors, leading to symptoms such as abdominal pain, bloating, diarrhea, constipation, and weight loss. Early diagnosis and effective treatment are crucial for managing these conditions, as some can progress to chronic or life-threatening stages if left untreated. Creative Biolabs offers comprehensive preclinical research services utilizing animal models to study digestive system diseases. Our services include in vitro and in vivo studies to assess disease mechanisms, evaluate therapeutic interventions, and test drug efficacy. Using advanced animal models, we provide tailored research to support the development of novel treatments and diagnostic tools for digestive system disorders.

Disease Models

Creative Biolabs offers a wide range of well-established rodent models for digestive system diseases, including models for inflammatory bowel disease (IBD), colitis, gastric ulcers, and liver disorders. These models are meticulously designed to simulate human digestive diseases and are accompanied by comprehensive evaluations of various parameters, enabling the accurate assessment of therapeutic candidates during the preclinical phase. Our team of experienced scientists will work collaboratively with you throughout your project, from experimental design to data interpretation, ensuring high-quality and reliable results. To learn more about the digestive system disease models available for preclinical research, please explore the links below:

Disease Models	Modeling Methods
Gastric Ulcer Models	Ethanol induced Gastric Ulcer Model
	Acetic Acid induced Gastric Ulcer Model
	Indomethacin induced Refractory Gastric Ulcer Model
Gastritis Models	DOCA & Ethanol & Ammonia Water induced Chronic Atrophic Gastritis Model
Colitis Models	TNBS/DNBS induced Colitis Model
	DSS induced Colitis Model
	Indomethacin induced Small Intestinal Inflammatory Model
	OXA induced Colitis Model
	Acetic Acid induced IBD Model
	Anti-CD40 Ab induced IBD Model
	IL-10 KO Mouse Spontaneous IBD Model
	CD4⁺CD45RB^hi T Cells induced IBD Model
Acute Pancreatitis Models	Sodium Taurocholate induced Acute Pancreatitis Model
	Cerulein induced Acute Pancreatitis Model
	Caerulein & LPS induced Acute Pancreatitis Model
Chronic Pancreatitis Models	Cerulein induced Chronic Pancreatitis Model
Diarrhea Models	5-Fluorouracil (5-Fu) induced Diarrhea Model
Diarrhea Models	Antibiotic induced Diarrhea Model
Emesis Models	Cisplatin induced Emesis Model
Emesis Models	GLP-1RA induced Emesis Model

Fig.1 Protocol for investigating the correlation between inflammatory bowel disease and the extent of myocardial infarction severity. (OA Literature) Fig.1 Protocol to examine the relationship between inflammatory bowel disease and severity of myocardial infarction.¹

Measurements

We offer a variety of measurements for evaluating drug efficacy in digestive system disease models, utilizing an array of advanced technologies, including but not limited to:

General observations: body weight, mortality rate, stool consistency, and gastrointestinal bleeding.
Cytokine profiling (e.g., ELISA): Expression levels of inflammatory mediators such as TNF-α, IL-6, and IL-1β.
Hematology analysis and serum biomarkers (e.g., liver enzymes, bilirubin levels).
Gene/protein expression profiling via RT qPCR and Western blot techniques.
Immunohistochemistry: Infiltration of immune cells (e.g., T-cells, macrophages) in gastrointestinal tissues.

In addition to the established digestive disease models, our expertise extends to the development of novel animal models tailored to specific research needs, guided by literature and prior studies. Our scientific team is available to assist in experimental design, model selection, and data analysis, ensuring a customized and effective approach to your project at every stage.

Related Services

Explore our comprehensive range of preclinical models beyond digestive system diseases, designed to support diverse therapeutic research.

Cardiovascular Disease Models

Neurological Disorder Models

Metabolic Disease Models

Urological System Disease Models

Respiratory Disease Models

Ocular Disease Models

Musculoskeletal Disease Models

Tumor Models

Inflammation & Immunological Disease Models

Infectious Disease Animal Models

Ear Disorder Models

Reproductive System Disease Models

Skin Disease Models

Advantages

Comprehensive Model Selection: We offer a wide range of well-established models for various digestive system diseases, such as inflammatory bowel disease (IBD), colitis, gastric ulcers, and liver disorders. This provides flexibility and ensures that the most suitable model can be selected for specific research needs.
Advanced Detection Methods: Utilization of cutting-edge technologies, such as cytokine profiling, immunohistochemistry, RT-qPCR, and Western blot, ensures precise and reliable data on drug efficacy and disease mechanisms. This enables thorough and accurate assessments of therapeutic interventions.
Tailored Research Support: Our experienced scientists offer personalized support throughout the research process, from experimental design to final data analysis. This ensures that the research is optimized for the most relevant and reliable results.
In-Depth Analysis of Disease Mechanisms: With a focus on histopathological, molecular, and immune assessments, the company provides a deeper understanding of disease pathology, facilitating the identification of novel therapeutic targets and mechanisms.
Customizable Models for Specific Needs: Our expertise in developing new and customized animal models ensures that the models can be tailored to meet specific research objectives. This flexibility improves the relevance and accuracy of preclinical findings.

Work with Us

Inquiry Stage

Summarize project requirements and fill in information collection form
Sign CDA for further communication on targets
Select animal model, discuss experimental design, determine assay parameters
Project costing and schedule forecasting

Project Start

Provide detailed project plan with sample quantities, methods, protocols
Both parties confirm details and start project
Confirm project timeline

Project Progress

Provide periodic results and animal condition updates
Collaborate on necessary project adjustments

Project Completion

Provide comprehensive project report promptly
Arrange transportation for produced samples
Discuss results and help arrange next steps

After-Sales Support

Data storage and archiving

Get in touch!

Frequently Asked Questions

Q1: How do we confirm the project after execution?

A1: Once the project is confirmed, we provide a detailed project plan, including required sample quantities and experimental details. After mutual agreement on the plan, we officially begin the project.
Q2: How is project progress monitored?

A2: Throughout the project, we regularly update clients on the progress, animal status, and any necessary adjustments. Clients are kept informed with timely reports, ensuring transparency and collaboration.
Q3: What happens when the project is completed?

A3: Upon completion, we provide the client with a comprehensive report summarizing the project's results. We also arrange for the shipment of any produced samples. Discussions regarding the results and next steps will follow.
Q4: What does after-sales support include?

A4: After the project is completed, we store the data for future reference and provide any necessary assistance with follow-up or additional analysis if required.
Q5: How long does the entire process take?

A5: The timeline depends on the scope and complexity of the project. During the pricing inquiry stage, we provide an estimated timeline, which is refined after the project execution plan is confirmed.

Published Data

An IBD model was established by dextran sulfate sodium (DSS) administration in drinking water, alone or with oral C. albicans (Ca) gavage. Histopathological examination of the gastrointestinal tract in this rodent model was conducted to assess the extent of inflammation. (A) Histopathology scores were assigned to each organ and specific section of the gastrointestinal tract based on the severity of damage. (B) An overall gastrointestinal tract inflammation score was calculated for each experimental group, reflecting the extent of the inflammatory response. (C) Representative H&E-stained colon sections (40× magnification) were examined to assess tissue damage. (D) Representative images of the colon at day 17 were taken, and colon length was measured across different experimental groups to assess the impact of DSS treatment on gastrointestinal function.

Fig.2 Histopathological examination of the gastrointestinal tract in animals treated with DSS. (OA Literature) Fig. 2 Histological analysis of the gastrointestinal tract in DSS-treated animals.¹

Reference

Mami, Wael et al. "Inflammatory Bowel Disease Increases the Severity of Myocardial Infarction after Acute Ischemia-Reperfusion Injury in Mice." Biomedicines vol. 11,11 2945. 1 Nov. 2023, doi:10.3390/biomedicines11112945. Distributed under an Open Access license CC BY 4.0, without modification.